Dev: Covid-19 Funding Opportunities

COVID-19 Research Grants for Combating the coronavirus crisis

Various government agencies, companies, and foundations have announced non-dilutive funding opportunities to encourage research and development to address the novel Coronavirus pandemic. Some of these opportunities allow applicants to propose new projects addressing COVID-19, while others provide funding to expand the scope of existing awards to include COVID-19-related research.

As the COVID-19 situation continues to develop, EGC will maintain an updated list of relevant funding opportunities here. Click below to be notified as new COVID-19 research grants are announced.

Expand/Collapse All
Biomedical Advanced Research and Development Authority (BARDA)

BARDA continues to solicit proposals for the development of diagnostic assays and therapeutics for COVID-19 and encourages applicants to participate in a TechWatch meeting prior to submitting a white paper or full proposal in response to its current Broad Agency Announcement

BARDA and Johnson & Johnson Innovation – JLABS

BLUE KNIGHT QuickFire Challenge: Next Generation Preparedness Solutions

Description: BLUE KNIGHT™ is a joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA) and seeks potentially ground-breaking ideas or technologies that aim to enhance preparedness towards future known and unknown infectious disease threats. The opportunity is open to innovators from any country. Up to four innovators will receive award funding from a total pool of $200,000 and access to the global Johnson & Johnson Innovation – JLABS network through Blue Knight residency, with mentorship from experts at the Johnson & Johnson Family of Companies and BARDA. The proposed idea or technology should align with mutual areas of interest between BARDA and the Johnson & Johnson Family of Companies.

Topics: Applicants must propose technologies that address at least one of the following focus areas:

  • Targeting the host response to known and unknown future infectious disease threats
  • Enabling streamlined manufacturing of therapeutics and/or vaccines
  • Leveraging the host microbiome

Due Dates: 7/22/2022
Budget: Awards will be drawn from a total pool of up to $200,000.


BARDA Broad Agency Announcement (BAA)

View Solicitation

Description: Proposals for diagnostic assay development are solicited under Area of Interest (AOI) 7.7 (AOI 7.7.1 Diagnostic Assay for Human Coronaviruses; AOI 7.7.2 Diagnostic Assay for Detection of SARS-CoV-2 Virus; AOI 7.7.3 Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies; and AOI 7.7.5 Screening Tests at Point of Care (2-minute Time to Result)). Additionally, under AOI 9.3 Immunomodulators or Therapeutics Targeting Lung Repair, BARDA seeks to develop immune modulators or other host-directed therapeutics promoting tissue repair that can prevent, treat, and/or improve clinical outcomes of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) caused by the pandemic or seasonal influenza and other respiratory viral infections. Only projects proposing clinical trials to evaluate the safety and efficacy of the proposed candidate therapeutic to prevent disease progression and/or reduce disease severity and mortality in hospitalized patients with ALI/ARDS due to influenza or other respiratory viral infections will be considered. Candidate therapeutics must have reached Technology Readiness Level 6 or higher.


DRIVe EZ-BAA

View Application Instructions

Description: BARDA’s s EZ-BAA aims to accelerate innovations and improve the availability of transformative products and technologies to protect Americans from natural and intentional health security threats. DRIVe is seeking transformative and innovative approaches that are outside of the mainstream, challenge assumptions, require multi-disciplinary teaming, and have the potential to radically change established practices, lead to extraordinary outcomes, and create entirely new fields. DRIVe is interested in projects that span the entire product development spectrum (but this may vary within each Area of Interest [AOI]).

Topics:

  • AOI #9:  Digital Health Tools for Pandemic Preparedness
  • AOI #10:  Next Generation Sequencing (NGS)-based Agnostic Diagnostic for Respiratory RNA Virus Pathogens
  • AOI #11a: Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2
  • AOI #11b: Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection

Due Dates: Applications are accepted on a rolling basis until 2/3/2023.
Budget: The total Government-funded share of the project budget should be less than $750,000.


TechWatch Meetings

Request a Meeting

Description: Through TechWatch meetings, the U.S. Government seeks information from stakeholders on available medical countermeasures in development, especially products, technologies, and capabilities that have progressed into or beyond clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products, technologies, or capabilities that are relevant to responses to public health emergencies (including COVID-19) is sought.

National Institutes of Health (NIH)
Notices of Special Interest (NOSI)

Multiple NIH Institutes have issued Notices of Special Interest (NOSIs) to provide funding for research topics related to COVID-19.  For most of these opportunities, the applicant must have an active award through the Institute with sufficient time remaining to complete all studies proposed.

Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities

Description: This Notice of Special Interest encourages researchers to pursue funding (via the R01 and R21 mechanisms) to conduct research addressing emerging and existing COVID-related issues among pregnant and lactating people, infants, children, and adolescents, and individuals with physical and/or intellectual disabilities. Its purpose is to complement the various COVID-related funding opportunities that are currently available by offering a funding opportunity to address key issues in the identified populations in ways that are not currently covered by available COVID-related funding announcements. Applications should fall within the mission of at least one of the following Institutes: the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), and the National Institute of Neurological Disorders and Stroke (NINDS).

Topics: Areas of interest include menstrual health, fertility, pregnancy, and perinatal issues; vaccination studies; pharmacology issues; developmental and schooling impacts; testing studies for COVID and related conditions; mental health concerns; viral strains and other viral issues; viral co-infections; pandemic effects; and neurological effects.

Due Date: Standard R01 and R21 submission dates apply. Expires 6/6/2024.
Budget: Not limited (R01); $275,000 in direct costs (R21)


Administrative Supplements for Research of Emerging and Existing Issues of COVID-19 Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities

Description: This Administrative Supplement provides an opportunity for funded researchers in various fields to pursue supplemental funding to conduct research addressing emerging and other existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. Its purpose is to complement existing COVID-related funding opportunities by supporting currently funded investigators in addressing key issues not covered by the available COVID-related funding announcements among these populations. Applications should fall within the mission of at least one of the following Institutes: the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Institute of Neurological Disorders and Stroke (NINDS).

Topics: Areas of interest include menstrual health, fertility, pregnancy, and perinatal issues; vaccination studies; pharmacology issues; developmental and schooling impacts; testing studies for COVID and related conditions; mental health concerns; viral strains and other viral issues; viral co-infections; pandemic effects; and neurological effects.

Due Date: May vary by awarding Institute/Center (IC). Please refer to the IC’s website for details.
Budget: Up to $100,000 in direct costs for NINDS; for other ICs, the total requested budget may not exceed the amount of the parent award.


National Eye Institute

Notice of Special Interest (NOSI): Addressing Accessibility Inequities with COVID Home-Based Testing for Individuals with Visual Impairment

Description: The National Eye Institute has issued a Notice of Special Interest to encourage the development and implementation of specific, targeted approaches for home-based COVID-19 testing that is accessible for people with visual impairment. Strategies should be scalable, sustainable, and consider the multiple stakeholders (e.g., visually impaired, blind children, adults with low vision, older adults, parents/guardians, caregivers).

Topics: Key issues to be addressed include but are not limited to:

  • Determining appropriate testing approaches (surveillance, screening, and/or diagnostic testing) for people who are visually impaired 
  • Reducing barriers to home -testing and establishing testing strategies suitable for people who are visually impaired
  • Developing new technologies to address current limitations

Due Date: Varies by funding opportunity
Budget: Varies by funding opportunity


National Institute of Mental Health (NIMR)
Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research

Description: The NIMH has issued a Notice of Special Interest in basic, translational, interventional, and services research relevant to the COVID-19 pandemic. A key area of interest is the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic, including not only those needs that are specifically related to the virus but also the needs of the broader population that is impacted by stress, disruptions, and loss of lives in the pandemic. Applicants may submit proposals to the R01, R21, and R34 programs.

Topics: Relevant topics of interest include the following:

  • Projects to develop and test tools that would enable health and social service workers to have real-time access to resources for case management and referral to medical/psychiatric treatment, as well as social support services, to meet the complex needs of persons with mental illness.
  • Research to determine the feasibility and utility of technology-enabled screening to identify/triage those in immediate need of in-patient behavioral health, medications, and opioid replacement therapy. Higher priority research would include evaluation of participant follow through and outcomes related to point-of-care triage and referral to services (e.g., web-based or other self-care, and/or telephone counseling that supports individual brief cognitive behavioral therapy (CBT) for distress, online group interventions, etc.).
  • Development and testing of technology to leverage/build on the available response workforce to enable practical, scalable, and sustainable mental health screening, triage, and prevention/treatment interventions along a continuum of intensity for mental disorders across the lifespan, particularly for high-risk populations both within and outside healthcare settings (i.e., school or workplace screening is also of interest). Interventions appropriate for mass trauma response are of interest (e.g., Psychological First Aid [PFA]; enhanced PFA; self-guided and professionally assisted skills-based interventions, internet-based interventions for managing common posttraumatic symptoms and stress related symptoms and conditions; brief CBT-based approaches for distress, and Collaborative Care programs) as are those to improve de-escalation of suicidal crises, reduce suicide attempt risk, and/or improve post-acute recovery for youth at elevated risk for self-injurious thoughts and behaviors treated in acute care settings).

Due Date: Varies by program
Budget: Varies by program


Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Required/Clinical Trial Optional)

Website: PA-22-112(Clinical Trial Required), PA-22-113(Clinical Trial Optional)

Description: This Funding Opportunity Announcement aims to address urgent, time-sensitive mental health research questions related to COVID-19, including broader secondary impacts of the pandemic as well as research on the intersection of mental health, COVID-19, and HIV. Research supported will improve public health in the near term by informing responses to the current pandemic through rapid acceleration of research to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions to respond to new and worsening mental illness and HIV-related outcomes among those who experience COVID-19 as well as the broader population impacted by the pandemic. All research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting health disparities.

Topics: Areas of high program priority are outlined in the funding opportunity announcements.

Due Date: 4/25/2022, 8/25/2022, and 12/23/2022
Budget: $750,000 in direct costs per year for up to 3 years

Other US Funding Sources Organization: North Carolina Collaboratory

Business-Academia Partnership Program 2022: COVID-19 Public Health and Economic Impacts in North Carolina

Description: The North Carolina Collaboratory, headquartered at the University of North Carolina at Chapel Hill (UNC-Chapel Hill), is requesting collaborative proposals from business-academic partnerships that seek to either develop innovative technologies or apply existing technologies to monitor, assess, and address the public health and/or economic impacts of COVID-19. Eligible applicants are for-profit or nonprofit business entities collaborating with an academic research group affiliated with an institution of higher learning located in North Carolina. No matching funds are required, and funding may be requested for projects lasting up to 36 months.

Topics: No specific topics are identified.

Due Dates: 8/1/2022
Budget: $300,000 to $3,000,000

International Opportunities Global Innovation Fund

GIF COVID-19 Response

Description: The Global Innovation Fund is a non-profit innovation fund that invests in the development, rigorous testing, and scaling of innovations targeted at improving the lives of the world’s poorest people, i.e., those living on less than $5 a day. For-profit companies located anywhere in the world can apply for funding for projects that address COVID-19 in developing countries. GIF supports innovators at all stages of their life cycle, from start-up and pilot-testing through to larger-scale implementation.

Topics: Innovations to assist with COVID-19 response and related issues affecting people living on less than $5 a day in developing countries.

Due Dates: Applications are accepted on a rolling basis
Budget: $50,000 to $15,000,000 depending upon project stage and needs. Grants are available to for-profit companies where appropriate, but other forms of investment are also used.